Sign in

CIK 0001719714

  • Non-accelerated filer
  • Smaller reporting company

Mereo BioPharma Group plc

Sign in to watch
Ticker
MREO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
United Kingdom
Entity type
Operating
Phone
+44 3330237300
Business address
ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, United Kingdom, W1G 0QF
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Open-market sale Chief Executive Officer sold 88,657 shares at an average $4.30 ($381,423)
  8. 4 Open-market sale Chief Scientific Officer sold 16,149 shares at an average $4.30 ($69,477)
  9. 4 Open-market sale General Counsel sold 30,926 shares at an average $4.30 ($133,051)
  10. 4 Open-market sale Chief Financial Officer sold 28,286 shares at an average $4.30 ($121,693)
  11. 4 Open-market sale Hughes-Wilson Alexandra sold 148,110 shares at an average $4.30 ($637,203)
  12. 4 Exercise or conversion General Counsel acquired 65,600 shares (option exercise)
  13. 4 Exercise or conversion Chief Financial Officer acquired 60,000 shares (option exercise)
  14. 4 Exercise or conversion Chief Scientific Officer acquired 46,000 shares (option exercise)
  15. 4 Exercise or conversion Chief Executive Officer acquired 188,060 shares (option exercise)
  16. 4 Exercise or conversion Hughes-Wilson Alexandra acquired 208,333 shares (option exercise)
  17. 4 Open-market sale Director sold 105,244 shares at $4.43 ($466,210)
  18. 4 Open-market sale General Counsel sold 46,389 shares at an average $3.49 ($161,678)
  19. 4 Open-market sale Chief Scientific Officer sold 24,224 shares at an average $3.49 ($84,427)
  20. 4 Open-market sale Chief Financial Officer sold 42,429 shares at an average $3.49 ($147,876)

Page 2 of 4 · 80 filings